Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.30
CYTX's Cash to Debt is ranked lower than
76% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. CYTX: 1.30 )
Ranked among companies with meaningful Cash to Debt only.
CYTX' s 10-Year Cash to Debt Range
Min: 0.3  Med: 6.14 Max: N/A
Current: 1.3
Equity to Asset 0.05
CYTX's Equity to Asset is ranked lower than
92% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CYTX: 0.05 )
Ranked among companies with meaningful Equity to Asset only.
CYTX' s 10-Year Equity to Asset Range
Min: -0.83  Med: 0.10 Max: 0.94
Current: 0.05
-0.83
0.94
F-Score: 6
Z-Score: -11.31
M-Score: -3.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -256.69
CYTX's Operating margin (%) is ranked lower than
64% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. CYTX: -256.69 )
Ranked among companies with meaningful Operating margin (%) only.
CYTX' s 10-Year Operating margin (%) Range
Min: -3958.33  Med: -244.92 Max: -68.58
Current: -256.69
-3958.33
-68.58
Net-margin (%) -305.73
CYTX's Net-margin (%) is ranked lower than
67% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. CYTX: -305.73 )
Ranked among companies with meaningful Net-margin (%) only.
CYTX' s 10-Year Net-margin (%) Range
Min: -3620.2  Med: -240.66 Max: -30.65
Current: -305.73
-3620.2
-30.65
ROA (%) -84.65
CYTX's ROA (%) is ranked lower than
80% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. CYTX: -84.65 )
Ranked among companies with meaningful ROA (%) only.
CYTX' s 10-Year ROA (%) Range
Min: -138.62  Med: -64.74 Max: -7.8
Current: -84.65
-138.62
-7.8
ROC (Joel Greenblatt) (%) -1549.62
CYTX's ROC (Joel Greenblatt) (%) is ranked lower than
67% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. CYTX: -1549.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2502.62  Med: -817.04 Max: -173.31
Current: -1549.62
-2502.62
-173.31
Revenue Growth (3Y)(%) -22.00
CYTX's Revenue Growth (3Y)(%) is ranked lower than
69% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CYTX: -22.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -11.25 Max: 97.2
Current: -22
0
97.2
EBITDA Growth (3Y)(%) -9.50
CYTX's EBITDA Growth (3Y)(%) is ranked lower than
56% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. CYTX: -9.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27.3  Med: -12.90 Max: 37.5
Current: -9.5
-27.3
37.5
EPS Growth (3Y)(%) -7.70
CYTX's EPS Growth (3Y)(%) is ranked lower than
51% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. CYTX: -7.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYTX' s 10-Year EPS Growth (3Y)(%) Range
Min: -41.5  Med: -12.55 Max: 102.7
Current: -7.7
-41.5
102.7
» CYTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CYTX Guru Trades in Q2 2014

Paul Tudor Jones 14,633 sh (+1.39%)
» More
Q3 2014

CYTX Guru Trades in Q3 2014

Jim Simons 475,131 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2014

CYTX Guru Trades in Q4 2014

Jim Simons Sold Out
» More
Q2 2015

CYTX Guru Trades in Q2 2015

George Soros 22,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CYTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 36.00
CYTX's P/B is ranked lower than
97% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CYTX: 36.00 )
Ranked among companies with meaningful P/B only.
CYTX' s 10-Year P/B Range
Min: 2.93  Med: 40.60 Max: 792
Current: 36
2.93
792
P/S 3.52
CYTX's P/S is ranked higher than
78% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. CYTX: 3.52 )
Ranked among companies with meaningful P/S only.
CYTX' s 10-Year P/S Range
Min: 3.42  Med: 12.93 Max: 43.94
Current: 3.52
3.42
43.94
Current Ratio 3.22
CYTX's Current Ratio is ranked lower than
59% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. CYTX: 3.22 )
Ranked among companies with meaningful Current Ratio only.
CYTX' s 10-Year Current Ratio Range
Min: 1.01  Med: 3.34 Max: 26.46
Current: 3.22
1.01
26.46
Quick Ratio 2.77
CYTX's Quick Ratio is ranked lower than
61% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CYTX: 2.77 )
Ranked among companies with meaningful Quick Ratio only.
CYTX' s 10-Year Quick Ratio Range
Min: 0.66  Med: 3.10 Max: 24.95
Current: 2.77
0.66
24.95
Days Inventory 460.98
CYTX's Days Inventory is ranked lower than
95% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. CYTX: 460.98 )
Ranked among companies with meaningful Days Inventory only.
CYTX' s 10-Year Days Inventory Range
Min: 36.86  Med: 210.95 Max: 529.06
Current: 460.98
36.86
529.06
Days Sales Outstanding 25.63
CYTX's Days Sales Outstanding is ranked higher than
80% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. CYTX: 25.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTX' s 10-Year Days Sales Outstanding Range
Min: 4.15  Med: 49.30 Max: 124.26
Current: 25.63
4.15
124.26

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.31
CYTX's Price/Median PS Value is ranked higher than
92% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. CYTX: 0.31 )
Ranked among companies with meaningful Price/Median PS Value only.
CYTX' s 10-Year Price/Median PS Value Range
Min: 0.42  Med: 1.07 Max: 3.36
Current: 0.31
0.42
3.36
Earnings Yield (Greenblatt) (%) -58.37
CYTX's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. CYTX: -58.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYTX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -67.46  Med: 0.00 Max: 0
Current: -58.37
-67.46
0

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 14 29 112 185
EPS($) -0.25 -0.12 0.76 1.38
EPS without NRI($) -0.25 -0.12 0.76 1.38

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XMPA.Germany,
Cytori Therapeutics Inc was incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celution System, which extracts the naturally occurring ADRCs from a patient's own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue banking lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe. Celution Systems are or will be subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for CYTX

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 
5-year lows: Fuel Systems Solutions Inc, Dawson Geophysical Co, Forest Oil Corp, and Cytori Therapeu Sep 08 2014 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: SSP, HPOL, CYTX, AGYS, VRX, TPI Mar 19 2012 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 09 2010 
Cytori Therapeutics Inc (CYTX) CFO Mark E Saad buys 6,000 Shares May 21 2010 
cooldecency99 note on CYTX May 01 2010 
creiter note on CYTX Jan 03 2010 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 10 2009 
Cytori Reports 2nd Quarter 2009 Financial Results Aug 10 2009 

More From Other Websites
Cytori Therapeutics to Provide Corporate Update and Investor Presentation Live, at... Sep 03 2015
Cytori Therapeutics to Provide Corporate Update and Investor Presentation Live, at... Sep 03 2015
Cytori Therapeutics to Provide Corporate Update and Investor Presentation Live, at... Sep 03 2015
Enrollment Begins in Cytori Phase III/Pivotal ADRESU Urinary Incontinence Trial Sep 03 2015
Enrollment Begins in Cytori Phase III/Pivotal ADRESU Urinary Incontinence Trial Sep 03 2015
Enrollment Begins in Cytori Phase III/Pivotal ADRESU Urinary Incontinence Trial Sep 03 2015
Cytori Therapeutics (CYTX) in Focus: Stock Rises 15% Sep 01 2015
Edited Transcript of CYTX earnings conference call or presentation 6-Aug-15 9:30pm GMT Aug 28 2015
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Other Events Aug 27 2015
CYTORI THERAPEUTICS, INC. Financials Aug 21 2015
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Aug 13 2015
10-Q for Cytori Therapeutics, Inc. Aug 12 2015
CYTORI THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 10 2015
Cytori Reports Second Quarter 2015 Business and Financial Results Aug 06 2015
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 06 2015
Cytori Reports Second Quarter 2015 Business and Financial Results Aug 06 2015
Enrollment Begins in Cytori U.S. Phase III/Pivotal Scleroderma Trial Aug 06 2015
Enrollment Begins in Cytori U.S. Phase III/Pivotal Scleroderma Trial Aug 06 2015
Japanese Approval Trial for Stress Urinary Incontinence Using Cytori Cell Therapy Announced Jul 30 2015
Japanese Approval Trial for Stress Urinary Incontinence Using Cytori Cell Therapy Announced Jul 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK